EVAX Evaxion A/S
Financings ·
Evaxion says its cash can fund operations into the second half of 2027, after a $7.5 million option exercise fee and a debt conversion with the European Investment Bank. The release reports a cash burn of about $14 million for 2026 and names no bank or agent for its amended at-the-market facility.
Evaxion says its public float now passes $75.0 million, which lifts a sales cap and allows up to $45.52 million more in ADS sales through JonesTrading. The float figure uses an October share price, and the stock was $6.28 in early December.
Evaxion says it restored stockholders' equity above the $2.5 million minimum and has cash runway into mid-2026. Nasdaq imposed a one-year monitor.
Each ADS now represents fifty ordinary shares instead of ten. The company says the change is meant to support liquidity in its ADSs on Nasdaq.
Evaxion A/S is a TechBio company that uses its AI-Immunology platform to develop vaccines for cancer and infectious diseases, and it plans to expand into autoimmune diseases. The company says the platform has been developed over 18 years, can be scaled to more than 100 different diseases, and works with different vaccine modalities. Its most advanced cancer vaccine, EVX-01, targets neoantigens and is being evaluated as a treatment for advanced melanoma. The company says 81% of the vaccine neoantigen targets in EVX-01 trigger a tumor-specific immune response. Its EVX-03 and EVX-04 candidates target endogenous retrovirus tumor antigens for precision cancer vaccines. For infectious diseases, the pipeline includes vaccines against pathogens for which no vaccines exist today, including S. aureus, Group A streptococcus, N. gonorrhoeae and cytomegalovirus. Its gonorrhoea candidate, EVX-B2, has achieved preclinical Proof of Concept and shows strong efficacy against 50 clinically relevant bacteria strains. Evaxion is a Danish company that began operations in August 2008, and its ADSs trade on the Nasdaq Capital Market under the symbol EVAX.
| Product or program | What it is | Stage |
|---|---|---|
| AI-Immunology platform | AI platform for identifying vaccine targets and suggesting vaccine designs | |
| EVX-01 | Cancer vaccine targeting neoantigens, evaluated for advanced melanoma | being evaluated as a treatment for advanced melanoma |
| EVX-03 and EVX-04 | Cancer vaccine candidates targeting endogenous retrovirus tumor antigens | |
| EVX-B2 | Gonorrhoea vaccine candidate with broad coverage of clinical strains | preclinical Proof of Concept |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $7.5 million | $3.3 million |
| Research and development | $10.0 million | $10.5 million |
| Net income (loss) | -$7.7 million | -$10.6 million |
| Cash from operations | -$6.6 million | -$12.9 million |
| Cash and equivalents | $23.2 million | $6.0 million |
Our latest story on this, dated Feb 14, 2025: "Nasdaq withdraws Evaxion Biotech (now Evaxion A/S) delisting determination". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 5, 2026: "Evaxion says cash funds operations into second half of 2027". The story links the filing or release it is based on. Read the story.
Evaxion A/S trades under the ticker EVAX on NASDAQ.
Evaxion A/S is listed on NASDAQ.
The SEC Central Index Key (CIK) for Evaxion A/S is 1828253. Its filings are on SEC EDGAR.
417,010,756 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-05.
Our directory records Evaxion A/S under Denmark.
Our directory classifies Evaxion A/S as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Evaxion A/S is US29970R3030.
aibio.space lists Evaxion A/S among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as G7.
Evaxion A/S is a TechBio company that uses its AI-Immunology platform to develop vaccines for cancer and infectious diseases, and it plans to expand into autoimmune diseases. The company says the platform has been developed over 18 years, can be scaled to more than 100 different diseases, and works with different vaccine modalities.
AI-Immunology platform: AI platform for identifying vaccine targets and suggesting vaccine designs
EVX-01: Cancer vaccine targeting neoantigens, evaluated for advanced melanoma Stage: being evaluated as a treatment for advanced melanoma.
$7.5 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Reported a financing. SEC Form 6-K. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a financing. SEC Form 6-K. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio